CARLOS
TAXONERA SAMSO
Profesor asociado de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (109)
2024
-
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588
2023
-
Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis
Alimentary Pharmacology and Therapeutics, Vol. 57, Núm. 6, pp. 610-619
2022
-
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis
Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 4, pp. 614-624
-
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83
-
Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis—Author’s reply
Alimentary Pharmacology and Therapeutics
-
Editorial: real-world safety of tofacitinib in ulcerative colitis
Alimentary Pharmacology and Therapeutics
-
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Biomedicines, Vol. 10, Núm. 3
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
Journal of Clinical Medicine, Vol. 11, Núm. 13
-
Real-World Effectiveness and Safety of Tofacitinib in Patients with Ulcerative Colitis: Systematic Review with Meta-Analysis
Inflammatory Bowel Diseases, Vol. 28, Núm. 1, pp. 32-40
-
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641
-
Recommendations for the detection of latent tuberculosis infection in patients with immune-mediated inflammatory diseases candidates for anti-TNF therapy may not be applicable in all settings
Rheumatology International
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: An example of evidence-based extrapolation
Revista Espanola de Enfermedades Digestivas
-
Can COVID-19 Trigger De Novo Inflammatory Bowel Disease?
Gastroenterology
-
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
Journal of Crohn's and Colitis, Vol. 15, Núm. 6, pp. 879-913
-
Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures
Inflammatory bowel diseases, Vol. 27, Núm. 6, pp. 864-869